Influenza virus-IN-6_product_DataBase

Bioactivity	Influenza virus-IN-6 (Compound 35) is a potent influenza N-terminal domain of the polymerase acidic protein subunit (PAN) endonuclease inhibitor with an IC50 of 0.20 μM[1].
Target	IC50: 0.20 μM (PAN)KD: 56.02 nM (PAN)
Invitro	Influenza virus-IN-6 (Compound 35) (48 h) 具有有抗流感病毒活性，在 MDCK 细胞中对 H1N1、H5N1、H3N2 和 Flu B 的 EC50 分别为 1.28 ± 0.35、1.12 ± 0.65、0.76 ± 0.11 和 0.43 ± 0.06 μM[1]。Influenza virus-IN-6 (5-20 μM; 24 h) 影响病毒复制，但不影响病毒颗粒、细胞和吸附[1]。Influenza virus-IN-6 (2.5-10 μM; 24 h) 抑制流感病毒聚合酶活性[1]。Influenza virus-IN-6 在小鼠血浆、肝微粒体和肠道 S9-UDPGA 中显示出良好的稳定性[1]。 Western Blot Analysis[1] Cell Line:
In Vivo	Influenza virus-IN-6 (Compound 35) (7.5-30 mg/kg/d; i.p.; twice daily for 7 days) 显著保护小鼠免受流感病毒感染[1]。Pharmacokinetic (PK) Profile In Vivo of Influenza virus-IN-6 (Compound 35) after a Single Dose in Rats In Vivo (n = 5)a[1] parameter
Name	Influenza virus-IN-6
Formula	C27H26ClNO7
Molar Mass	511.95
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Liao Y, et al. Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PAN Endonuclease Inhibitors. J Med Chem. 2022 Dec 15.

PeptideDB